STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
Double-digit growth journey continues with 16% sales increase to €2.1bn1 and 30% EBITDA to €509 million[1] in first six months of 2023 Organic growth in Consumer Healthcare is largest contributor to record performance; Specialty segment with double-digit growth as well. Market-share gains in Generics STADA CEO Peter Goldschmidt: “STADA’s purpose, values and strategy are the base for our continue